Testosterone cypionate
- Generic Name
- Testosterone cypionate
- Brand Names
- Depo-testosterone
- Drug Type
- Small Molecule
- Chemical Formula
- C27H40O3
- CAS Number
- 58-20-8
- Unique Ingredient Identifier
- M0XW1UBI14
- Background
Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester. Its benefit compared to other testosterone derivatives is the slow rate of release after injection and longer half-life. It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.
- Indication
Testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone. These conditions are 1) primary hypogonadism, defined as the testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; and 2) hypogonadotropic hypogonadism characterized by idiopathic gonadotropin, LHRH deficiency or pituitary-hypothalamic injury from tumors, trauma or radiation.
- Associated Conditions
- Hypergonadotropic Hypogonadism, Hypogonadotrophic Hypogonadism
- Associated Therapies
- -
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
- Conditions
- Castration Resistant Metastatic Prostate Cancer
- Interventions
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 150
- Registration Number
- NCT04363164
- Locations
- 🇺🇸
Dana-Faber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.